IDStewardship
JUNE 19, 2025
AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.
Pharmacy Times
JULY 16, 2025
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. 2 Vepdegestrant is an oral PROTAC that targets ER and is the first agent of its type to be evaluated in a phase 3 trial.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 18, 2025
Image credit: OM | stock.adobe.com Why Proper Disposal Matters Disposing of medications appropriately helps prevent environmental contamination of water and soil. Safe disposal options include DEA Take Back Days, pharmacy kiosks, law enforcement kiosks, mail-back envelopes, and home disposal methods.
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A. 2,3 Hypertension remains a major public health challenge both in the United States and globally.
Pharmacy Times
JULY 1, 2025
SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.
Pharmacy Times
JUNE 16, 2025
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.
Pharmacy Times
JUNE 10, 2025
3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. 2 REFERENCES 1. Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism. December 21, 2004. Subscribe Now!
Expert insights. Personalized for you.
130 
Let's personalize your content